MENLO PARK, Calif., April 25, 2016 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced that it has completed enrollment for its Phase 2a study of the novel topical minocycline gel BPX-01.
The Phase 2a study will assess the safety of BPX-01 in 30 patients randomized to 30 days of treatment with either BPX-01 or a placebo. The endpoints of this study include reduction of Propionibacterium acnes (P. acnes) and cutaneous tolerance of the BPX-01 formulation.
“This research is important to the dermatology community, which has been searching for an effective alternative to current oral antibiotic acne treatments,” said AnnaMarie Daniels, executive vice president of clinical and regulatory affairs for BioPharmX. “Our preclinical tests show the potential of BPX-01, which we believe may be able to offer dermatologists a safe, effective treatment for one of the most common skin conditions in the world.”
Nonclinical studies show the unique BPX-01 topical gel formulation of minocycline can penetrate the epidermis to deliver the antibiotic to the dermis layer of skin where the condition develops. BPX-01 is the first and only stable hydrophilic (non-oil-based) topical gel with fully solubilized minocycline, the antibacterial and anti-inflammatory medicine most commonly prescribed to treat acne vulgaris. It is anticipated that BPX-01 may effectively treat acne with lower, and therefore potentially safer, dosages of the antibiotic.
The FDA has previously found oral minocycline to be safe. However, the high dosage required to make the oral version effective against acne often causes undesirable side effects. BPX-01 is highly anticipated by the dermatology community as a break-through alternative to the oral products currently available.
Phase 2a is expected to end by mid-year.
About BioPharmX® Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company that seeks to provide products through proprietary platform technologies for prescription, over-the-counter and supplement applications in dermatology and women’s health. To learn more about BioPharmX, visit www.BioPharmX.com.
Forward-Looking Statement
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. This press release contains forward-looking statements about the company’s expectations, plans, intentions and strategies, including, but not limited to, statements regarding, enrollment and results of the company’s Phase 2a study of BPX-01, the completion date of the Phase 2a study and the effectiveness of the BPX-01 formulation. These forward-looking statements may be identified by words such as “plan”, “expect,” “anticipate,” “believe,” or similar expressions that are intended to identify such forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in the company’s filings with the Securities and Exchange Commission. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
BioPharmX is a registered trademark of BioPharmX, Inc.
Logo - http://photos.prnewswire.com/prnh/20150711/235327LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biopharmx-announces-full-patient-enrollment-in-phase-2a-study-of-bpx-01-topical-antibiotic-for-acne-300256312.html
SOURCE BioPharmX Corporation
